Jump to Main Content
Making Targeted Therapy Compatible with Checkpoint Immunotherapy
- Fernández, Ariel
- Trends in biotechnology 2017
- T-lymphocytes, antibodies, cross reaction, immunotherapy, mutation, neoplasms
- Immune checkpoint blockades induced by antibodies are revolutionizing cancer therapy., Combinations of checkpoint immunotherapies with kinase inhibitors (KIs) are being clinically evaluated as oncogenic mutations arise. Off-target KI cross-reactivity will often compromise synergistic efficacy, with KIs suppressing T cell functionalities that checkpoint blockers are purportedly boosting. This incompatibility may be removed through molecular optimization.